Trial comparing treatments for Non-Small Cell Lung Cancer
Official title A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06793215
What this study is testing
What is Divarasib?
Divarasib is an investigational oral medicine being studied for the first‑line treatment of KRAS G12C‑mutated advanced or metastatic non‑squamous non‑small cell lung cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares how well divarasib and pembrolizumab treat KRAS G12C‑mutated advanced lung cancer versus the usual chemo plus pembrolizumab. It also looks at safety of the two approaches.
- Who it's for
- Adults with advanced or metastatic non‑squamous non‑small cell lung cancer that has a KRAS G12C mutation and who have not received prior treatment.
- What's involved
- Participants receive either divarasib and pembrolizumab or the standard chemotherapy (pemetrexed with carboplatin or cisplatin) plus pembrolizumab. They will have regular clinic visits, blood tests, imaging scans, and other safety checks.
- Time commitment
- The study lasts about 2 years, with frequent visits during the first 6 months and then every 3 months for follow‑up.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or...
- Measurable disease, as defined by RECIST v1.1
- No prior systemic treatment for advanced or metastatic NSCLC
- Documentation of the presence of a KRAS G12C mutation
You likely can't join if
- Known concomitant second oncogenic driver with available targeted treatment
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without...
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of...
See the full eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
- Measurable disease, as defined by RECIST v1.1
- No prior systemic treatment for advanced or metastatic NSCLC
- Documentation of the presence of a KRAS G12C mutation
- Documentation of known PD-L1 expression status in tumor tissue
- Availability of a representative tumor specimen
- Adequate end-organ function
- Eligible to receive a platinum-based chemotherapy regimen
- Known concomitant second oncogenic driver with available targeted treatment
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>=2 weeks prior to...
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study
- Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung \>30Gy within 6 months prior to randomization
- Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
- Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors
- Current treatment with medications that are well known to prolong the QT interval
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization
- History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate \>90%), such as...
- Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or...
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed...
- Significant cardiovascular disease within 3 months prior to screening
The study team makes the final eligibility decision.
Where it is enrolling
- Anchorage, Alaska, United States
- Goodyear, Arizona, United States
- Clovis, California, United States
- Greenbrae, California, United States
- Irvine, California, United States
- Los Angeles, California, United States
- Newport Beach, California, United States
- Orange, California, United States
- Palo Alto, California, United States
- Roseville, California, United States
- San Francisco, California, United States
- Colorado Springs, Colorado, United States
- Fort Collins, Colorado, United States
- Grand Junction, Colorado, United States
- Hartford, Connecticut, United States
- Fort Myers, Florida, United States
- Gainesville, Florida, United States
- Hialeah, Florida, United States
- Hollywood, Florida, United States
- Miami, Florida, United States
+ 232 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Anchorage, Alaska, United States; Goodyear, Arizona, United States; Clovis, California, United States; Greenbrae, California, United States; Irvine, California, United States; Los Angeles, California, United States and 246 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.